Validation of the GenePOC GBS Assay for the Detection of the Cfb Gene From Streptococcus Agalactiae Strains

NCT ID: NCT02718157

Last Updated: 2021-05-03

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

771 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-08-10

Study Completion Date

2017-02-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of this clinical investigation is to verify the performance of the GenePOC GBS Assay on the GenePOC Instrument. This will be achieved by comparing the Assay to the a Culture, a conventional method for detection of Streptococcus agalactiae in vaginal/rectal swab specimens from antepartum women.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The GenePOC GBS Test performed on the GenePOC System is a qualitative in vitro diagnostic (IVD) test designed to detect Group B Streptococcus (GBS) DNA from vaginal/rectal swabs from antepartum women following enrichment in Lim broth for 18-24 hours.

The GenePOC GBS Test utilizes automated sample preparation and real-time polymerase chain reaction (PCR) to detect a cfb gene sequence specific to the Streptococcus agalactiae genome. The GenePOC GBS Test is indicated for the identification of antepartum GBS colonization and does not provide susceptibility results. Culture isolates are needed for performing susceptibility testing as recommended for penicillin-allergic women.

The GenePOC GBS is an IVD system is comprised of the GenePOC Diagnostics System and the GenePOC Group B Step \[GBS\] Test, the components of which are:

1. Instrument
2. GBS disposable microfluidic cartridges (PIE) (described in this document as PIEs because of the shape of the cartridge)
3. GBS Sample Buffer Tube (SBT)
4. Sample Transfer Device (STD).

The GenePOC Instrument is fully automated and integrates sample lysis, dilution, amplification and detection of the target sequence in complex samples using real-time Polymerase chain reaction (rtPCR). User intervention is only required for discharging the patient sample into the SBT (sample Buffer Tube), transferring the sample into the PIE and for loading/unloading the PIEs into the instrument. The GenePOC instrument consists of a rotor to spin the PIEs, temperature control, fluorescence detection, a tactile user-friendly interface, two barcode readers, and integrated firmware and software to deliver results to the user. The PIE is a closed system that prevents the risk of contamination.

Lim Broth is used for the selective enrichment of group B streptococci (Streptococcus agalactiae). An aliquot of the broth is mixed with GenePOC Sample Buffer Tube Reagent (SBT), after which a sample is transferred to the GenePOC GBS PIE. The GenePOC GBS PIE is then automatically processed by the GenePOC Instrument.

On completion of a run, the user removes the processed PIEs from the instrument and discards them according to local biological waste management procedures.

One GenePOC instrument per site will be allocated. The purpose of the clinical investigation is to enroll sufficient specimens from four (4) Clinical Centers to obtain a total of 150 specimens positive for GBS based on the Reference Method final result.

Subject Informed consent is not required for this clinical trial as the testing will be performed on excess de-identified specimens only.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Streptococcus Agalactiae Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Accuracy Testing

Comparison between GenePOC PCR and Reference Method

Group Type EXPERIMENTAL

Comparison between GenePOC PCR and Reference Method

Intervention Type DEVICE

Antepartum women swab specimen incubated in Lim Broth will be tested with the GenePOC GBS test on the GenePOC Instrument. The results will be compared to Reference Method defined as incubated Lim broth subcultured onto blood agar plate for observation of a Streptococcus agalactiae strain.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Comparison between GenePOC PCR and Reference Method

Antepartum women swab specimen incubated in Lim Broth will be tested with the GenePOC GBS test on the GenePOC Instrument. The results will be compared to Reference Method defined as incubated Lim broth subcultured onto blood agar plate for observation of a Streptococcus agalactiae strain.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Antepartum pregnant women
* 18 years old and more
* Being at a gestation period of 35 to 37 weeks.
* Vaginal/rectal swab specimen
* Transport and storage times, and conditions (e.g. room temperature and/or refrigerated) within the labeled indications.

* Fresh specimens available to be tested with the GenePOC GBS System within 96 hours (4 days) of collection if kept at 2-25°C
* Fresh specimens must be tested with the Reference Method within 96 hours (4 days) of collection if kept at 2-25°C
* The GenePOC GBS System and the Reference Method will be performed according to the GenePOC GBS Investigation Documents.
* Materials use within their expiration date

* The GenePOC GBS System and the Reference Method not performed according to the GenePOC GBS Investigation Documents.

Exclusion Criteria

* Non pregnant women
* Less than 18 years old
* Gestation not between 35-37 weeks
* Transport and storage times and conditions that exceed these Study Protocol requirements
* The GenePOC GBS System and the Reference Method not performed according to the GenePOC GBS Investigation Documents
* Materials used beyond their expiration date
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Meridian Bioscience, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Patrice Allibert

Role: STUDY_DIRECTOR

Meridian Bioscience, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Detroit Medical Center University Laboratories

Detroit, Michigan, United States

Site Status

Tricore Laboratory University of New Mexico

Albuquerque, New Mexico, United States

Site Status

Mount Sinai Hospital Joseph and Wolf Lebovic Health Complex

Toronto, Ontario, Canada

Site Status

CHU de Québec - Université Laval

Québec, , Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GenePOC-GBS_clinical-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Maternal- Fetal Infection
NCT03371056 UNKNOWN NA
Group A Streptococcus Saliva Study
NCT06473506 ACTIVE_NOT_RECRUITING NA